New Ventures BC 2009 Finalist Indel Therapeutics Inc.’s patented antibiotic discovery technology is helping to more rapidly generate new antibiotics for combating drug-resistant and hospital-acquired infections.
Infections such as Methicillin-resistant Staphylococcus aureus (MRSA) are a huge concern for hospital administrators as there is growing incidence each year of nasty and sometimes deadly bacteria plaguing hospitals. In the United States alone, about 1.7 million people get hospital-acquired infections each year, killing about 99,000 people a year and costing the US health system $27.5 billion annually.
Indel’s novel approach provides an advantage against the emergence of antibiotic resistance and opens a new area of drug targeting in a therapeutic area where there is a lack of and a tremendous need for new drugs.
Indel Therapeutics is based in Vancouver and its intellectual property originated at the University of British Columbia.